USP, Angels for Change, and Vizient Collaborate to Improve Supply Chain for Pediatric Drugs

USP partnered with a patient advocacy group and procurement organization to create a predictive model for improving supply chain resilience for critical pediatric oncology drugs.

The United States Pharmacopeia (USP) announced on May 13, 2021 that it has partnered with Angels for Change, a nonprofit patient advocacy group, and Vizient, a group purchasing organization, to develop a predictive model for improving its 17 supply chain. pediatric oncology drugs, 13 of which have known shortages in the past three years. Expertise and data were brought together to provide insights to prevent and / or mitigate supply chain disruptions for suppliers and patients and to create the Drug Supply Resiliency Model.

The three organizations worked together to collect data on the shortage of medicines for pediatric oncology. Angels for Change, in consultation with clinical experts, has identified 17 drugs for the pilot project. USP, who developed the model, contributed upstream supply chain data by leveraging insights from more than 22,000 locations using USP standards. USP also used its Medicine Supply Map to analyze the 17 drugs identified. Vizient, which identifies drugs that could be affected by supply chain disruptions, has provided downstream demand data.

“Pediatric oncology drugs have long been at high risk of deficiency, and this affects hospital costs and has resulted in unfavorable outcomes for the patient. The Drug Supply Resiliency Model, which builds on the Pediatric Drug Shortage Project implemented by CHA and Vizient, helps us quantify root causes and further identify solutions as we work to eliminate pediatric drug shortages, ”said Terri Wilson, Director of Supply Chain Services– Pharmacy at Children’s Hospital Association and a consultant to the project, in a press release.

“Understanding upstream supply chain risks is important for governments, GPOs and manufacturers to prioritize investments in improving supply chain resilience. Supply chain data for medicines is fragmented, but private sector collaborations such as this one can bring together a more complete picture and help governments, GPOs, manufacturers and other stakeholders work together to improve supply chain resilience and prevent patients with disabilities. shortage of medicines. , ”Said Stephen Schondelmeyer, co-principal investigator of the Resilient Drug Supply Project at the Center for Infectious Diseases Research and Policy (CIDRAP) at the University of Minnesota and advisor to the project, in the press release.

Source: USP

Comments are closed.